Clinical trial
Efficacy and Safety of ATL-962 in Obese Diabetics
NCT00156897 · Alizyme, Industry · Completed
Key facts
| NCT number | NCT00156897 |
|---|---|
| Title | Efficacy and Safety of ATL-962 in Obese Diabetics |
| Official title | Multicentre Double Blind Placebo Controlled Parallel Group Dose Ranging Study of ATL-962 to Assess Weight Loss, Safety and Tolerability in Obese Patients With Type II Diabetes Being Treated With Metformin, in Comparison With Orlistat |
| Lead sponsor | Alizyme, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Insulin-Dependent Diabetes Mellitus, Obesity |
| Intervention type | Drug |
| Interventions | ATL-962, Orlistat |
| Enrollment | 600 |
| Start date | Dec 1, 2004 |
| Completion | Oct 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Aug 29, 2006 |
| Countries | Denmark, Finland, Netherlands, Sweden, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: